Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Newron Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will be participating on a panel discussion entitled, "Innovative Treatment Approaches to Orphan CNS Developmental Disorders" at the JMP Securities Life Sciences Conference on Wednesday, June 19th, 2019 at 10:00 a.m. EDT. The panel will focus on novel pharmacological approaches to treating orphan genetic disorders that primarily impact the central nervous system.

About Newron Pharmaceuticals
Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The company is headquartered in Bresso near Milan, Italy. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson's disease in the European Union, Switzerland, the US, Australia, Canada, Brazil, and Colombia and is commercialized by Newron's partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson's disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com

These press releases may also interest you

at 03:25
Causaly, the AI company teaching computers to read, understand and interpret biomedical knowledge, is pleased to announce its series A fundraising round, which saw new and existing investors commit $4.8m into the company. Pentech Ventures led the...

at 03:05
AgraFlora Organics International Inc.  ("AgraFlora" or the "Company") , a growth oriented and diversified international cannabis company, is pleased to announce the Company has entered into a preferred supply agreement (the "Supply Agreement") with...

at 03:00
The United States Environmental Protection Agency (EPA) reports that mold in schools can be caused by a variety of conditions. ServPro Morro Bay, mold damage specialists, has recently released a report about managing mold in schools to help parents...

at 02:58
Important events July - September NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroSTAT receives Fast Track designation from the US Food and Drug Administration.Financial information third quarter (July-September...

at 02:47
Covance was honored with the 2019 Global CRO Customer Value Leadership award from Frost & Sullivan at the annual Frost & Sullivan Asia-Pacific Best Practices Awards banquet held in Singapore on 14 November 2019. Frost & Sullivan firmly believes...

at 02:28
Biovica, active in cancer biomarkers, today announced that clinical data - demonstrating that DiviTum can be used as a dynamic, non-invasive biomarker for metastatic breast cancer patients treated with endocrine therapy and palbociclib - will be...

News published on 13 june 2019 at 07:05 and distributed by: